טוען...
Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy
OBJECTIVE: Bevacizumab, the first FDA-approved anti-angiogenesis agent, has been used for metastatic colorectal cancer since 2004. This study evaluated the utilization of bevacizumab among elderly metastatic colorectal cancer patients in the United States. METHODS: Using Surveillance and Epidemiolog...
שמור ב:
| הוצא לאור ב: | J Oncol Pharm Pract |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4883010/ https://ncbi.nlm.nih.gov/pubmed/24122849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155213507010 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|